COVID-19 Guide for the Rehabilitation Clinician:

A Review of Non-Pulmonary Manifestations and Complications

Marielisa Lopez, MD\textsuperscript{1}; Kathleen Bell, MD\textsuperscript{1}; Thiru Annaswamy, MD\textsuperscript{1,2}; Shannon Juengst, PhD\textsuperscript{1}; Nneka Ifejika, MD\textsuperscript{1}

\textsuperscript{1}Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX; \textsuperscript{2}Physical Medicine & Rehabilitation Service, VA North Texas Health Care System, Dallas, TX

Correspondence: Marielisa Lopez, MD, Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, 5151 Harry Hines Boulevard, CS6.104C, Dallas, TX 75390-8860

Author Disclosures: No conflicts of interest have been reported by the authors.

Funding: No funding received
Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as COVID-19 – is primarily known for respiratory illness. While it is clear that patients with moderate to severe cases of COVID-19 will require pulmonary rehabilitation, physiatrists will need to consider effective management plans for COVID-19 survivors with extra-pulmonary involvement. This report will summarize key non-pulmonary considerations to guide rehabilitation clinicians who may be involved in the care of COVID-19 survivors with the best available early evidence.

**Key Words:** COVID-19; Complications; Manifestations; Rehabilitation
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as COVID-19 – is primarily known for respiratory illness. Infection with the virus triggers a cytokine release storm causing high levels of inflammation, which then results in pulmonary damage characterized by edema, prominent proteinaceous exudates, vascular congestion, and inflammatory clusters with fibrinoid material and multinucleated giant cells and the prominent clinical symptom of hypoxia. One or more storms may occur, causing additional systemic injury. While it is clear that patients with moderate to severe cases of COVID-19 will require pulmonary rehabilitation, physiatrists will need to consider effective management plans for COVID-19 survivors with extra-pulmonary involvement.

The COVID-19 literature continues to expand; currently, observational single institution reports and case series with relatively small sample sizes are our primary sources of evidence. This report will summarize key non-pulmonary considerations to provide early guidance to rehabilitation clinicians who may be involved now in the care of COVID-19 survivors with the best available evidence to date.

Neurologic

- SARS-CoV and other human coronaviruses are neuroinvasive and neurotropic. They can also be neurovirulent, causing illnesses like meningitis and encephalitis. Respiratory viruses can enter the central nervous system (CNS) through hematogenous spread, or the peripheral nervous system through axonal transmission. The olfactory nerve, trigeminal nerve or the sensory fibers of the (PNS) vagus nerve are the most common peripheral nerve targets. Similar to mice models, it is possible that SARS-CoV-2 may persist in the CNS, utilizing a theory that supports viral triggers of neurologic diseases such as Multiple Sclerosis. Since SARS-CoV and
SARS-CoV2 have high similarity, SARS-CoV2 may also have the potential to invade the nervous system.

- Brain tissue is reported to have angiotensin converting enzyme –2 (ACE-2) receptors. The SARS-CoV-2 uses the SARS-CoV receptor ACE2 for host cell entry at the myocardial cell membrane. Some researchers have proposed access of SARS-COV-2 through the cribriform plate to the brain with the potential of endothelial capillary damage, resulting in hemorrhage within the cerebral tissues. Further confirmatory investigation is needed.

- Some patients with severe COVID-19 (78 in a study of 214) have had neurological manifestations including altered consciousness, central nervous system symptoms (headache, dizziness, impaired consciousness, ataxia, acute cerebrovascular events and epilepsy), and PNS symptoms (hypoguesia, hyposmia, hypopsia, and neuralgia). While there are new reports of young healthy patients sustaining strokes due to coagulopathy (https://www.washingtonpost.com/health/2020/04/24/strokes-coronavirus-young-patients/), these data have not yet been published and true incidence of stroke is not yet known.

- An observational series of 58 consecutive patients in France admitted with acute respiratory distress syndrome (ARDS) due to Covid-19, reported agitation and confusion (40/58), dysexecutive syndrome (14 of 39 discharged patients) and corticospinal tract signs (39/58). Two of 13 patients who underwent brain MRI because of unexplained encephalopathic features, had single acute ischemic strokes. Data is lacking to determine which features were specific to SARS-CoV-2 infection.
In a multi-institutional observational series in Italy comprising approximately 1200 patients admitted with COVID-19, five patients were diagnosed with Guillain-Barré syndrome after the onset of disease. Four had positive nasopharyngeal swab for SARS-CoV-2 at onset of disease and one had a negative nasopharyngeal swab but subsequently converted to positive on serologic testing. All the patients had negative real-time polymerase-chain-reaction SARS-CoV-2 assay of the CSF. The findings were generally consistent with an axonal variant of Guillain–Barré syndrome in three of the patients and with a demyelinating process in the remaining two.

Hematologic

- A case series of 3 patients with confirmed SARS-CoV-2 described positive antiphospholipid antibodies and subsequent multiple cerebral infarctions. One patient also had evidence of ischemia in lower limbs and several digits of the hand.
- A Netherlands report evaluated thrombotic complications in 184 ICU patients with COVID-19 infection in which the incidence was found to be 31%. Pulmonary embolism was the most frequent thromboembolic complication.

Musculoskeletal

- Skeletal muscle injury has been seen in 17 out of 214 patients with severe COVID-19 disease, characterized by elevated creatinine kinase and lactate dehydrogenase. Prolonged immobility in the intensive care unit could be the etiologic cause of these symptoms.
- Additionally, there is a case report of a patient hospitalized for COVID-19 who, on day 9 of hospitalization, presented with pain and weakness in lower limbs with
positive tenderness. Myoglobin, creatinine kinase and lactate dehydrogenase were elevated along with liver enzymes, suggesting rhabdomyolysis. No confirmation of pathology consistent with rhabdomyolysis was available\\textsuperscript{11}.

**Ocular**

- In a meta-analysis with three studies including 1167 patients, it was reported the overall rate of conjunctivitis at admission to the hospital was 1.1% (3% and 0.7% in severe and non-severe COVID-19 patients), respectively\\textsuperscript{12}.
- There was a single case report of bilateral acute conjunctivitis and positive reverse transcription-polymerase chain reaction (RT-PCR) SARS-CoV-2 in conjunctival swabs, with swabs remaining positive for 17 days\\textsuperscript{13}.

**Cardiovascular**

- ACE-2 is expressed in the cardiovascular system during severe infections. Patients with underlying cardiovascular disease can be especially susceptible to the pro-arrhythmic effects, with co-existing fever, electrolyte disturbances, stress and the use of antiviral drugs. Aggressive antipyretic treatment and electrocardiogram (ECG) monitoring is recommended in some patients\\textsuperscript{14}.
- There is an additional case report of a patient with positive SARS-CoV-2 with acute myopericarditis, with signs and symptoms of heart failure a week after upper respiratory tract symptoms began\\textsuperscript{15}.
- While the mechanism of cardiac injury is not fully described, several mechanisms have been proposed, including immune inflammatory response, viral invasion to
cardiomyocytes, severe hypoxia and oxidative stress with myocardial injury from increased myocardial oxygen demand\textsuperscript{16}.

- There is one case series of patients (n=3) who showed decompensation of underlying heart failure, ST segment elevation, and cardiogenic shock concurrent with COVID-19\textsuperscript{17}.
- Like patients with exacerbations of COPD and/or community acquired pneumonia, survivors of COVID will likely be at high risk of cardiovascular events and mortality, especially in the 30 days following the resolution of the acute phase of the virus\textsuperscript{18}.
- In a single-center series in China involving 138 patients with COVID-19 pneumonia, 10 were found with laboratory evidence of acute myocardial injury via significantly higher cardiac biomarkers CK-MB (creatinine kinase myocardial band) and hs-cTnI (high sensitivity cardiac troponin I)\textsuperscript{19}.

### Gastrointestinal

- Earlier studies of SARS indicated that the gastrointestinal tract tropism of SARS coronavirus (SARS-CoV) was verified by the viral detection in biopsy specimens and stool even in discharged patients. The increased gastrointestinal wall permeability with virus infection and subsequent enteric symptoms like diarrhea due to invaded enterocytes malabsorption suggest that the digestive system might be vulnerable to COVID-19 infection\textsuperscript{20}.
- Chai et al.\textsuperscript{21} showed that specific ACE-2 expression in cholangiocytes may cause liver damage after COVID-19 infection. The liver abnormalities of COVID-19 patients may not be due to hepatocyte damage, but rather cholangiocyte dysfunction,
and with systemic illnesses, there may be non-specific elevations of liver enzymes as well.

- In a large cohort including 1099 patients from 552 hospitals in 31 provinces or provincial municipalities and of those with available results of liver enzymes, patients with more severe disease had abnormal liver aminotransferase levels than did patients with non-severe disease\textsuperscript{22}.

- In 52 patients with COVID-19 pneumonia, the incidence was 33\% for heart injury (abnormal LDH or CK), 29\% for liver injury (any abnormality in AST, ALT, GGT or ALP), 17\% for pancreatic injury, 8\% for renal injury (abnormal creatinine), and 2\% for diarrhea. There is potential for mild pancreatic injury patterns in patients with COVID-19 pneumonia, and these may be related to direct viral involvement of the pancreas or from secondary enzyme abnormalities in the context of severe illness without substantial pancreatic injury. These patients also had abnormal blood glucose\textsuperscript{23} with implications for patients with pre-existing diabetes mellitus.

- In a retrospective study with 206 patients with mild COVID-19, nearly one-quarter (48) had digestive symptoms only, 69 displayed both digestive and respiratory symptoms, and 89 had respiratory symptoms only. Of the patients with digestive symptoms (117), 67 had diarrhea, the study found\textsuperscript{24}.

- Viral RNA can be detected in the stool of 81.8\% (54/66) of cases, even with negative results for throat swabs. Compared to SARS, patients with COVID-19 experienced diarrhea, nausea, vomiting and/or abdominal discomfort less often before respiratory symptoms. However, feces as a potential contagious source of viral RNA can last even after viral clearance in the respiratory tract. It is strongly recommended that all
recovered COVID-19 patients disinfect and clean their toilets until 17 - 20 days after negative blood tests and respiratory disorder recovery.²⁵

**Dermatologic**

- From collected data in 88 COVID-19 patients in Italy, 18 (20.4%) developed skin manifestations including 8 at the onset of disease and 10 after hospitalization. Manifestations included erythematous rash, urticarial and chickenpox-like vesicles. Lesions seemed to heal within a few days.²⁶

It will be imperative for continued data to be collected on these patients during the recovery and rehabilitation stage in order to sort acute reactions to sepsis from intrinsic actions of the novel coronavirus. Additionally, many of these patients will be experiencing symptoms related to stress disorders, anxiety, or depression. It is highly likely that many of these patients will be cared for on inpatient rehabilitation units and as outpatients in physical medicine and rehabilitation clinics and early establishment of registries to document symptom clusters and recovery trajectories will inform rehabilitation management during the next year.

This brief report can serve as a guide for the rehabilitation clinician in different scenarios we have considered including: 1) Determining screening criteria for admission to the post-acute setting with the knowledge that there can be many extra-pulmonary symptoms and viral shedding can occur outside of the respiratory system. According to the CDC “SARS-CoV-2 can cause asymptomatic, pre-symptomatic, and minimally symptomatic infections, leading to viral shedding that may result in transmission to others who are particularly vulnerable to severe disease and death”²⁷. In consideration of this, identifying any of the clinical findings discussed in
this report during the pre-admission assessment in a patient with no documented respiratory symptoms leading to acute care hospital, along with clinical judgement, can prompt testing prior to admission and also justify medical complexity for admission to an inpatient rehab facility (IRF). Even though viral shedding in stool has been identified even after throat swabs are negative\textsuperscript{25}, at this time the CDC reports that the risk of infection through stool is low\textsuperscript{28}. Until more studies are available, standard precautions should be exercised during toileting activities. 2) Increase clinical awareness and guide need for COVID-19 testing in patients in IRF and skilled nursing facility (SNF) settings when only non-respiratory symptoms are present. Screening tests used in existing studies, presented in Table 1, could serve as guidance for further diagnostic investigation depending on the sign or symptom. 3) Inform of risks of other medical complications that may arise requiring monitoring and management in the post-acute inpatient and outpatient settings. In particular, the elevated potential for cardiac arrhythmias may require additional monitoring as patients begin participation in aerobic reconditioning. Laboratory monitoring for improvement after end-organ injury (i.e. liver, pancreas, cardiac) might also be warranted during an IRF stay.

As mentioned previously, in most cases, available data cannot confirm that SARS-CoV-2 infection directly relates to these findings, so caution should be exercised when considering implementation of this information into clinical practice. Current data are preliminary and no practice-based guidelines are available. However, the best currently available evidence can help guide treatment decisions in conjunction with clinical expertise and patient preferences. Rehabilitation clinicians should implement an Evidence Based Physiatry approach to clinical care, combining their individual clinical expertise with evolving external evidence while engaging patients in the decision-making process\textsuperscript{29}. 
Acknowledgements: None
References:

1. Tian S, Hu W, Niu L, et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients with Lung Cancer. *J Thorac Oncol* https://doi.org/10.1016/j.jtho.2020.02.010

2. Shi, Y., Wang, Y., Shao, C. et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ* 27, 1451–1454 (2020). https://doi.org/10.1038/s41418-020-0530-3

3. Desforges M, Le Coupancec A, Dubeau P, et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?. *Viruses*. 2019;12(1):14. Published 2019 Dec 20. doi:10.3390/v12010014

4. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients [published online ahead of print, 2020 Feb 27]. *J Med Virol*. 2020;10.1002/jmv.25728. doi:10.1002/jmv.25728

5. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci*. 2020;11(7):995–998. doi:10.1021/acschemneuro.0c00122

6. Mao I, Wang M, Mengdie, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study (February 24, 2020). Available at SSRN: https://ssrn.com/abstract=3544840 or http://dx.doi.org/10.2139/ssrn.3544840

7. Helms J, Kremmer A, Merdji Het al. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med*. DOI: 10.1056/NEJMc2008597
8. Toscaso G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med*. DOI: 10.1056/NEJMc2009191

9. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med*. 2020;382(17):e38. doi:10.1056/NEJMc2007575

10. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 [published online ahead of print, 2020 Apr 10]. *Thromb Res.* 2020;S0049-3848(20)30120-1. doi:10.1016/j.thromres.2020.04.013

11. Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19 [published online ahead of print, 2020 Mar 20]. *Emerg Infect Dis.* 2020;26(7):10.3201/eid2607.200445. doi:10.3201/eid2607.200445

12. Loffredo L, Pacella F, Pacella E, Tiscione G, Oliva A, Violi F. Conjunctivitis and COVID-19: a meta-analysis [published online ahead of print, 2020 Apr 24]. *J Med Virol.* 2020;10.1002/jmv.25938. doi:10.1002/jmv.25938

13. Chen L, Liu M, Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease [published online ahead of print, 2020 Apr 7]. *Br J Ophthalmol.* 2020;bjophthalmol-2020-316304. doi:10.1136/bjophthalmol-2020-316304

14. Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes [published online ahead of print, 2020 Mar 31]. *Heart Rhythm.* 2020;S1547-5271(20)30285-X. doi:10.1016/j.hrthm.2020.03.024

15. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. *JAMA Cardiol.* 2020;10.1001/jamacardio.2020.1096. doi:10.1001/jamacardio.2020.1096
16. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease [published online ahead of print, 2020 Mar 28]. *Int J Cardiol.* 2020;S0167-5273(20)31593-X. doi:10.1016/j.ijcard.2020.03.063

17. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19 [published online ahead of print, 2020 Apr 3]. *Circulation.* 2020;10.1161/CIRCULATIONAHA.120.047164. doi:10.1161/CIRCULATIONAHA.120.047164

18. Celli B, Fabbri LM. Urgent need of a management plan for survivors of COVID-19. *Eur Respir J.* 2020;55(4):2000764. Published 2020 Apr 23. doi:10.1183/13993003.00764-2020

19. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585.

20. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission [published online ahead of print, 2020 Mar 3]. *Gastroenterology.* 2020;. doi:10.1053/j.gastro.2020.02.054

21. Chai X, Hu L, Zhang Y, et al. (2020). Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. 10.1101/2020.02.03.931766.

22. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. *N Engl J Med.* 2020;NEJMoa2002032. doi:10.1056/NEJMoa2002032
23. Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia [published online ahead of print, 2020 Apr 1]. *Gastroenterology*. 2020; doi:10.1053/j.gastro.2020.03.055

24. Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes [published online ahead of print, 2020 Apr 15]. *Am J Gastroenterol*. 2020;10.14309/aig.0000000000000664. doi:10.14309/aig.0000000000000664

25. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients [published online ahead of print, 2020 Feb 28]. *Chin Med J* (Engl). 2020;10.1097/CM9.0000000000000774. doi:10.1097/CM9.0000000000000774

26. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective [published online ahead of print, 2020 Mar 26]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16387. doi:10.1111/jdv.16387

27. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html

28. Water and COVID-19 FAQs. https://www.cdc.gov/coronavirus/2019-ncov/php/water.html

29. Rizzo, John-Ross MD, MS; Paganoni, Sabrina MD, PhD; Annaswamy, Thiru M. MD, MA The “Nuts and Bolts” of Evidence-Based Physiatry, American Journal of Physical Medicine & Rehabilitation: October 2019 - Volume 98 - Issue 10 - p 942-943 doi: 10.1097/PHM.0000000000001269
| Body System | Clinical Findings | No. (% | Study Design | Screening Tests Used |
|-------------|------------------|--------|--------------|----------------------|
| Neurologic  | Altered consciousness, headache, dizziness, ataxia, acute cerebrovascular events, epilepsy, hypogeusia, hyposmia, hypopsia, neuralgia | 78/214 (36%) | Retrospective study | History and Exam, Head CT |
|             | Agitation and confusion | 40/48 (83%) | Observational series | The Confusion and Assessment Method for the ICU, Richmond Agitation and Sedation Scale, Physical Exam |
|             | Dysexecutive syndrome | 14/39 (36%) | Observational series | History and Exam, CSF analysis, MRI, Antiganglioside Antibodies, Electrophysiological studies |
|             | Corticospinal tract signs | 39/58 (67%) | Observational series | History and Exam, Prothrombin/partial thromboplastin time, D-dimer, Fibrinogen, Antiphospholipid antibodies |
|             | Guillain-Barré Syndrome | 5/~1200 (0.4%) | Observational series | CT pulmonary angiography, Ultrasonography, CT head |
|             | Positive antiphospholipid antibodies, lower limb ischemia, hand digit ischemia | 3 | Case series | Creatinine kinase, Lactate dehydrogenase, Myoglobin, C-reactive protein |
|             | Pulmonary embolism, other venous thromboembolic events, arterial thrombotic events (ischemic stroke) | 31/184 (17%) | Observational series | Creatinine kinase, Lactate dehydrogenase, Myoglobin, C-reactive protein |
|             | Rhabdomyolysis | 17/214 (8%) | Retrospective case series | Creatinine kinase, Lactate dehydrogenase, Myoglobin, C-reactive protein |
|             | 1 | Case report | Creatinine kinase, Lactate dehydrogenase, Liver enzymes |
| Ocular      | Conjunctivitis | 13/1167 (1%) | Meta-analysis | Physical Exam, Conjunctival swab |
|             | 1 | Case report | Conjunctival swab |

Table 1. Summary of Potential Non-Pulmonary Manifestations and Complications of COVID-19 (continued)

Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
| Body System | Clinical Findings | No. (%) | Study Design | Screening Tests Used | Reference |
|-------------|-------------------|---------|--------------|----------------------|-----------|
| **Cardiovascular** | Myopericarditis and heart failure | 1 | Case report | Electrocardiography • HS-troponin T • NT-proBNP • Cardiac MRI | Inciardi et al\textsuperscript{15} |
| | Decomposition of underlying heart failure, ST segment elevation, cardiogenic shock | 3 | Case series | Electrocardiography • Troponin I • Transthoracic echocardiography • Chest radiography | Fried et al\textsuperscript{17} |
| | Acute cardiac injury | 10/138 (7.2%) | Case series | CK-MB • hs-CtInl | Wang et al\textsuperscript{26} |
| **Gastrointestinal** | Abnormal AST | 168/757 (22.2%) | Cohort study | Aspartate aminotransferase • Alanine aminotransferase | Guan et al\textsuperscript{21} |
| | Abnormal ALT | 158/741 (21.3) | Cohort study | AST • ALT • GGT • ALP • Amylase • Lipase | |
| | Liver injury (AST, ALT, GGT or ALP abnormality) | 15/52 (29%) | Retrospective study | AST • ALT • GGT • ALP • Amylase • Lipase | Wang et al\textsuperscript{22} |
| | Pancreatic injury | 9/52 (17%) | Retrospective study | AST • ALT • GGT • ALP • Amylase • Lipase | |
| | Diarrhea | 1/52 (2%) | Retrospective study | AST • ALT • GGT • ALP • Amylase • Lipase | |
| | Digestive symptoms (Decreased appetite, vomiting, diarrhea, abdominal pain) | 117/206 | Retrospective study | History and Exam | Han et al\textsuperscript{21} |
| **Dermatologic** | Erythematous rash | 18/88 (20.4%) | Case series | History and Exam | Recalcati\textsuperscript{25} |
| | Widespread urticaria | | | | |
| | Chickenpox-like vesicles | | | | |

* CT denotes computed tomography, ICU intensive care unit, CSF cerebrospinal fluid, MRI magnetic resonance imaging, HS high sensitivity, NT N-terminal, B-type natriuretic peptide, CK-MB creatine kinase myocardial band, hs-Ctln high sensitivity cardiac troponin I, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase